IMMUNITYBIO, INC. Depreciation
IMMUNITYBIO, INC. (IBRX) reported Depreciation of $3.30 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-05-07
- IMMUNITYBIO, INC. depreciation for the quarter ending 2026-03-31 was $3.30M, a 0.00% change year-over-year.
- IMMUNITYBIO, INC. depreciation for the quarter ending 2025-12-31 was $3.30M, a 8.33% decline year-over-year.
- IMMUNITYBIO, INC. depreciation for the quarter ending 2025-09-30 was $3.40M, a 12.82% decline year-over-year.
- IMMUNITYBIO, INC. depreciation for the quarter ending 2025-06-30 was $3.40M, a 12.82% decline year-over-year.
- IMMUNITYBIO, INC. depreciation for fiscal 2025 was $13.40M, a 13.55% decline from fiscal 2024.
- IMMUNITYBIO, INC. depreciation for fiscal 2024 was $15.50M, a 6.06% decline from fiscal 2023.
- IMMUNITYBIO, INC. depreciation for fiscal 2023 was $16.50M, a 1.23% increase from fiscal 2022.
- IMMUNITYBIO, INC. depreciation for fiscal 2022 was $16.30M, a 14.79% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $3.30M 10-Q · filed 2026-05-07 | $6.60M derived: sum of 2 quarters · filed 2026-05-07 | $10.00M derived: sum of 3 quarters · filed 2026-05-07 | $13.40M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $6.70M derived: sum of 2 quarters · filed 2026-02-23 | $10.10M derived: sum of 3 quarters · filed 2026-02-23 | $13.40M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $3.40M 10-Q · filed 2025-11-05 | $6.80M derived: sum of 2 quarters · filed 2025-11-05 | $10.10M 10-Q · filed 2025-11-05 | $13.70M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-06-30 | $3.40M 10-Q · filed 2025-08-05 | $6.70M 10-Q · filed 2025-08-05 | $10.30M derived: sum of 3 quarters · filed 2026-05-07 | $14.20M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-03-31 | $3.30M 10-Q · filed 2026-05-07 | $6.90M derived: sum of 2 quarters · filed 2026-05-07 | $10.80M derived: sum of 3 quarters · filed 2026-05-07 | $14.70M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $7.50M derived: sum of 2 quarters · filed 2026-02-23 | $11.40M derived: sum of 3 quarters · filed 2026-02-23 | $15.50M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $3.90M 10-Q · filed 2025-11-05 | $7.80M derived: sum of 2 quarters · filed 2025-11-05 | $11.90M 10-Q · filed 2025-11-05 | $15.90M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | $3.90M 10-Q · filed 2025-08-05 | $7.90M 10-Q · filed 2025-08-05 | $12.00M derived: sum of 3 quarters · filed 2026-02-23 | $16.10M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $4.00M 10-Q · filed 2025-05-12 | $8.10M derived: sum of 2 quarters · filed 2026-02-23 | $12.20M derived: sum of 3 quarters · filed 2026-02-23 | $16.40M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.20M derived: sum of 2 quarters · filed 2026-02-23 | $12.40M derived: sum of 3 quarters · filed 2026-02-23 | $16.50M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $4.10M 10-Q · filed 2024-11-12 | $8.30M derived: sum of 2 quarters · filed 2024-11-12 | $12.40M 10-Q · filed 2024-11-12 | $17.10M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $4.20M 10-Q · filed 2024-08-12 | $8.30M 10-Q · filed 2024-08-12 | $13.00M derived: sum of 3 quarters · filed 2025-03-03 | $17.10M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $4.20M 10-Q · filed 2024-05-09 | $8.80M derived: sum of 2 quarters · filed 2025-03-03 | $12.90M derived: sum of 3 quarters · filed 2025-03-03 | $16.80M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $8.70M derived: sum of 2 quarters · filed 2025-03-03 | $12.60M derived: sum of 3 quarters · filed 2025-03-03 | $16.30M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $4.10M 10-Q · filed 2023-11-09 | $8.00M derived: sum of 2 quarters · filed 2023-11-09 | $11.70M 10-Q · filed 2023-11-09 | $15.40M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | $3.90M 10-Q · filed 2023-08-08 | $7.70M 10-Q · filed 2023-08-08 | $11.30M derived: sum of 3 quarters · filed 2024-03-19 | $15.00M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | $3.80M 10-Q · filed 2023-05-11 | $7.40M derived: sum of 2 quarters · filed 2024-03-19 | $11.10M derived: sum of 3 quarters · filed 2024-03-19 | $15.10M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $7.30M derived: sum of 2 quarters · filed 2024-03-19 | $11.30M derived: sum of 3 quarters · filed 2024-03-19 | $14.20M 10-K · filed 2024-03-19 | |
| 2021-09-30 | $3.70M 10-Q · filed 2022-11-09 | $7.70M derived: sum of 2 quarters · filed 2022-11-09 | $10.60M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $4.00M 10-Q · filed 2022-08-08 | $7.00M 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $8.20M derived: sum of 2 quarters · filed 2023-03-01 | $10.50M derived: sum of 3 quarters · filed 2023-03-01 | $12.70M 10-K · filed 2023-03-01 | $9.10M 10-K · filed 2021-03-04 |
| 2020-09-30 | $2.40M 10-Q · filed 2020-11-09 | $4.70M derived: sum of 2 quarters · filed 2020-11-09 | $6.90M 10-Q · filed 2020-11-09 | $9.10M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2020-06-30 | $2.30M 10-Q · filed 2020-08-07 | $4.50M 10-Q · filed 2020-08-07 | $6.70M derived: sum of 3 quarters · filed 2021-03-04 | $8.90M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2020-03-31 | $2.20M 10-Q · filed 2020-05-11 | $4.40M derived: sum of 2 quarters · filed 2021-03-04 | $6.60M derived: sum of 3 quarters · filed 2021-03-04 | $8.80M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $4.40M derived: sum of 2 quarters · filed 2021-03-04 | $6.60M derived: sum of 3 quarters · filed 2021-03-04 | $8.40M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $2.20M 10-Q · filed 2020-11-09 | $4.40M derived: sum of 2 quarters · filed 2020-11-09 | $6.20M 10-Q · filed 2020-11-09 | $8.40M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-06-30 | $2.20M 10-Q · filed 2020-08-07 | $4.00M 10-Q · filed 2020-08-07 | $6.20M derived: sum of 3 quarters · filed 2021-03-04 | $8.40M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-03-31 | $1.80M 10-Q · filed 2020-05-11 | $4.00M derived: sum of 2 quarters · filed 2021-03-04 | $6.20M derived: sum of 3 quarters · filed 2021-03-04 | $8.00M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2018-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $4.40M derived: sum of 2 quarters · filed 2021-03-04 | $6.20M derived: sum of 3 quarters · filed 2021-03-04 | $7.30M 10-K · filed 2021-03-04 | |
| 2018-09-30 | $2.20M 10-Q · filed 2019-11-05 | $4.00M derived: sum of 2 quarters · filed 2019-11-05 | $5.10M 10-Q · filed 2019-11-05 | $6.10M derived: sum of 4 quarters · filed 2020-03-25 | |
| 2018-06-30 | $1.80M 10-Q · filed 2019-08-06 | $2.90M 10-Q · filed 2019-08-06 | $3.90M derived: sum of 3 quarters · filed 2020-03-25 | $4.80M derived: sum of 4 quarters · filed 2020-03-25 | |
| 2018-03-31 | $1.10M 10-Q · filed 2019-05-08 | $2.10M derived: sum of 2 quarters · filed 2020-03-25 | $3.00M derived: sum of 3 quarters · filed 2020-03-25 | $3.80M derived: sum of 4 quarters · filed 2020-03-25 | |
| 2017-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $1.90M derived: sum of 2 quarters · filed 2020-03-25 | $2.70M derived: sum of 3 quarters · filed 2020-03-25 | $3.30M 10-K · filed 2020-03-25 | |
| 2017-09-30 | $900.00K 10-Q · filed 2018-11-07 | $1.70M derived: sum of 2 quarters · filed 2018-11-07 | $2.30M 10-Q · filed 2018-11-07 | $2.90M derived: sum of 4 quarters · filed 2019-03-13 | |
| 2017-06-30 | $800.00K 10-Q · filed 2018-08-06 | $1.40M 10-Q · filed 2018-08-06 | $2.00M derived: sum of 3 quarters · filed 2019-03-13 | $2.30M derived: sum of 4 quarters · filed 2019-03-13 | |
| 2017-03-31 | $600.00K 10-Q · filed 2018-05-07 | $1.20M derived: sum of 2 quarters · filed 2019-03-13 | $1.50M derived: sum of 3 quarters · filed 2019-03-13 | $1.60M derived: sum of 4 quarters · filed 2019-03-13 | |
| 2016-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $900.00K derived: sum of 2 quarters · filed 2019-03-13 | $1.00M derived: sum of 3 quarters · filed 2019-03-13 | $1.00M 10-K · filed 2019-03-13 | |
| 2016-09-30 | $300.00K 10-Q · filed 2017-11-07 | $400.00K derived: sum of 2 quarters · filed 2017-11-07 | $400.00K 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $100.00K 10-Q · filed 2017-08-07 | $100.00K 10-Q · filed 2017-08-07 | |||
| 2016-03-31 | $37.00K 10-Q · filed 2017-05-08 | ||||
| 2015-12-31 | $100.00K 10-K · filed 2018-03-12 | ||||
| 2014-12-31 | $36.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |